Search details
1.
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
Blood
; 138(9): 758-772, 2021 09 02.
Article
in English
| MEDLINE | ID: mdl-33786575
2.
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Blood
; 137(18): 2481-2494, 2021 05 06.
Article
in English
| MEDLINE | ID: mdl-33171493
3.
miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.
Blood
; 132(22): 2389-2400, 2018 11 29.
Article
in English
| MEDLINE | ID: mdl-30213873
4.
The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy.
Haematologica
; 105(6): 1494-1506, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32482755
5.
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Blood
; 128(12): 1609-13, 2016 09 22.
Article
in English
| MEDLINE | ID: mdl-27480113
6.
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib.
Haematologica
; 106(11): 2995-2999, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-34196167
7.
MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
Leukemia
; 33(2): 403-414, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30111844
8.
DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines.
Oncol Rep
; 33(5): 2169-75, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25739012
9.
Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
Leukemia
; 32(9): 2028-2031, 2018 09.
Article
in English
| MEDLINE | ID: mdl-30030508
Results
1 -
9
de 9
1
Next >
>>